Small molecule-based therapy for Alzheimer’s disease: Slug/SNAI2 ameliorates cognitive deficits in Alzheimer’s disease patients via up regulation of its target gene, 9/June/2014, 8.00 am

Natural product-based therapy for Myocardial disorders: Garlic inhibits programmed myocardial necrosis and antagonizes myocardial infarction via up regulation of its target gene, 9/June/2015, 6.48 am
June 9, 2015
Molecular therapy for Hyperglycemia & T2DM: Antrodia salmonea increases the expression of AMPK(5′ adenosine monophosphate-activated protein kinase), decreases gluconeogenesis and fasting glucose level via up regulation of its target gene, 9/June/2015, 8.31 am
June 9, 2015
Show all

A recent study from the Department of Psychiatry and Psychotherapy, Georg-August-University Goettingen, Goettingen, Germany shows that “Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease.” This study was published in the 5 Jan’13 issue of the journal EMBO Mol Medicine.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small molecule-based therapy for Alzheimer’s disease: Slug/SNAI2 ameliorates cognitive deficits in Alzheimer’s disease patients via up regulation of its target gene

Significance: 

Given that: (1) in 2006, 26.6 million people worldwide’re afflicted by Alzheimer’s disease; (2) the number of cases diagnosed with Alzheimer’s disease may increase from 26.6 million people in 2006 to 106.4 million in 2050 worldwide; (3) Alzheimer’s disease is the forth leading cause of death in US in the elderly; (4) Alzheimer’s disease is the third most costly disease to treat only after cancer and coronary heart disease; and (5) US$80–100 billion spent in US in caring for patients diagnosed with Alzheimer’s disease, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; and (ii) a side-effect-free natural product-based drug.

This study suggests, for the first time, that Slug/SNAI2, by increasing the expression of its target gene, it may decrease the expression of HDAC6. Thereby, it may ameliorate cognitive deficits in Alzheimer’s disease patients. Thus, pharmacological formulations encompassing “Slug/SNAI2 activators” may be used to improve cognitive deficits in Alzheimer’s disease patients.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Small molecule-based therapy for Alzheimer’s disease: Slug/SNAI2 ameliorates cognitive deficits in Alzheimer’s disease patients via up regulation of its target gene, 9/June/2014,  8.00 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How  Slug/SNAI2  decreases HDAC6 expression

Comments are closed.